Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838367 | 0.96 | MAPT (0.44) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL12091364 | 0.94 | MAPT (0.43) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL402847 | 0.93 | MAPT (0.41) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL838083 | 0.92 | MAPT (0.49) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL10030725 | 0.92 | USP2 (0.41) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4747310 | 0.92 | MAPT (0.40) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4758832 | 0.92 | USP2 (0.41) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL14369609 | 0.92 | SMN1; SMN2 (0.46) | MAPTRAB9APOLBALDH1A1SMN1; SMN2 | |
| SCHEMBL1707907 | 0.92 | USP2 (0.50) | MAPTPOLBALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL401764 | 0.92 | RECQL (0.47) | MAPTPOLBSMN1; SMN2KMT2AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8449095-B2 | Radiation curable solid ink compositions suitable for transfuse printing applications | XEROX CORPORATION (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120013690-A1 | RADIATION CURABLE SOLID INK COMPOSITIONS SUITABLE FOR TRANSFUSE PRINTING APPLICATIONS | XEROX CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-7887176-B2 | High image quality in inkjet printing onto flexible packaging substrates of polyester, polypropylene, and aluminum foil, can be significantly improved by the use of radiation curable gel based phase change inks; not requiring pinning of the ink during color printing or nitrogen inerting during curing | XEROX CORPORATION (US) | 2011-02-15 | — | — | US | disclosed |
| US-7625956-B2 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2009-12-01 | — | — | US | disclosed |
| US-7279587-B2 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070120910-A1 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | NR2E3, NR4A1, NR4A3 | MAPT 2052/4885RAB9A 3663/4885POLB 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.